Over 60% of SLE patients demonstrate an “IFN signature” characterized by elevated IFN-regulated gene activity, with nearly 50% exhibiting sustained high IFN-I levels linked to genetic predisposition and enhanced disease risk (35). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.